177Lu-FAP-2286肽靶向放射性核素治疗多种腺癌的首次人体研究:可行性、生物分布与初步剂量学
本研究首次在人体中评估177Lu-FAP-2286用于肽靶向放射性核素治疗(PTRT)的可行性。11例经68Ga-FAP-2286或68Ga-FAPI-04 PET/CT确认摄取的晚期胰腺癌、乳腺癌、直肠癌或卵巢癌患者接受177Lu-FAP-2286治疗(5.8 ± 2.0 GBq;范围2.4-9.9 GBq),耐受良好,全身有效剂量为0.07 ± 0.02 Gy/GBq,肾脏和红骨髓平均吸收剂量分别为1.0 ± 0.6 Gy/GBq和0.05 ± 0.02 Gy/GBq,骨转移灶肿瘤吸收剂量高达3.0 ± 2.7 Gy/GBq,未观察到4级不良事件,3例发生3级事件。
要点
- 177Lu-FAP-2286 PTRT在多种晚期腺癌中耐受良好,无4级不良事件。
- 全身有效剂量0.07 ± 0.02 Gy/GBq,肾脏1.0 ± 0.6 Gy/GBq,红骨髓0.05 ± 0.02 Gy/GBq。
- 骨转移灶肿瘤吸收剂量达3.0 ± 2.7 Gy/GBq,显示显著摄取和长滞留。
核心结论
- 177Lu-FAP-2286 PTRT在广谱癌症中耐受性较好,副作用可接受,放射性肽在肿瘤中滞留时间长,值得开展前瞻性临床研究。
研究设计与样本
- 首次人体研究,纳入11例经68Ga-FAP-2286或68Ga-FAPI-04 PET/CT确认摄取的晚期胰腺癌、乳腺癌、直肠癌或卵巢癌患者,行177Lu-FAP-2286 PTRT。
主要发现
- 177Lu-FAP-2286给药活度为5.8 ± 2.0 GBq(范围2.4-9.9 GBq),所有患者耐受良好,未观察到或报告不良症状或临床可检测的药理效应。
- 全身有效剂量为0.07 ± 0.02 Gy/GBq(范围0.04-0.1 Gy/GBq)。
- 肾脏平均吸收剂量为1.0 ± 0.6 Gy/GBq(范围0.4-2.0 Gy/GBq),红骨髓为0.05 ± 0.02 Gy/GBq(范围0.03-0.09 Gy/GBq)。
- 骨转移灶肿瘤吸收剂量为3.0 ± 2.7 Gy/GBq(范围0.5-10.6 Gy/GBq),显示显著摄取和长滞留。
- 未观察到4级不良事件;3例发生3级事件(1例全血细胞减少、1例白细胞减少、1例疼痛 flare-up);3例报告疼痛缓解。
关键数值与推荐
- PTRT前需经68Ga-FAP-2286或68Ga-FAPI-04 PET/CT确认摄取。
- 177Lu-FAP-2286给药活度5.8 ± 2.0 GBq(范围2.4-9.9 GBq)。
- 全身有效剂量0.07 ± 0.02 Gy/GBq(范围0.04-0.1 Gy/GBq)。
- 肾脏吸收剂量1.0 ± 0.6 Gy/GBq(范围0.4-2.0 Gy/GBq),红骨髓0.05 ± 0.02 Gy/GBq(范围0.03-0.09 Gy/GBq)。
- 骨转移灶肿瘤吸收剂量3.0 ± 2.7 Gy/GBq(范围0.5-10.6 Gy/GBq)。
临床怎么用
- 对于FAP高摄取的晚期腺癌患者,177Lu-FAP-2286 PTRT可作为耐受性较好的治疗选择,但需关注血液学毒性和疼痛 flare-up。
- 治疗前应通过68Ga-FAP-2286或68Ga-FAPI-04 PET/CT筛选患者。
- 肾脏和红骨髓剂量学数据可用于个体化剂量评估。
局限性
- 本研究为首次人体小样本(11例)可行性研究,缺乏疗效对照和长期随访数据。
- 原文未报告肿瘤类型的具体分布、既往治疗史及剂量学方法的详细参数。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fibroblast activation protein (FAP) is a promising target for diagnosis and therapy of numerous malignant tumors. FAP-2286 is the conjugate of a FAP-binding peptide, which can be labeled with radionuclides for theranostic applications. We present the first-in-humans results using 177Lu-FAP-2286 for peptide-targeted radionuclide therapy (PTRT). Methods: PTRT using 177Lu-FAP-2286 was performed on 11 patients with advanced adenocarcinomas of the pancreas, breast, rectum, or ovary after prior confirmation of uptake on 68Ga-FAP-2286 or 68Ga-FAPI-04 PET/CT. Results: Administration of 177Lu-FAP-2286 (5.8 ± 2.0 GBq; range, 2.4-9.9 GBq) was well tolerated, with no adverse symptoms or clinically detectable pharmacologic effects being noticed or reported in any of the patients. The whole-body effective dose was 0.07 ± 0.02 Gy/GBq (range, 0.04-0.1 Gy/GBq). The mean absorbed doses for kidneys and red marrow were 1.0 ± 0.6 Gy/GBq (range, 0.4-2.0 Gy/GBq) and 0.05 ± 0.02 Gy/GBq (range, 0.03-0.09 Gy/GBq), respectively. Significant uptake and long tumor retention of 177Lu-FAP-2286 resulted in high absorbed tumor doses, such as 3.0 ± 2.7 Gy/GBq (range, 0.5-10.6 Gy/GBq) in bone metastases. No grade 4 adverse events were observed. Grade 3 events occurred in 3 patients-1 with pancytopenia, 1 with leukocytopenia, and 1 with pain flare-up; 3 patients reported a pain response. Conclusion:177Lu-FAP-2286 PTRT, applied in a broad spectrum of cancers, was relatively well tolerated, with acceptable side effects, and demonstrated long retention of the radiopeptide. Prospective clinical studies are warranted.
引用
- Baum RP, Schuchardt C, Singh A, et al. Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results. J Nucl Med. 2021. PMID: 34168013. doi:10.2967/jnumed.120.259192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。